China Expects M&A, Sharper Competition To Result From New Drug Policy
This article was originally published in PharmAsia News
Executive Summary
China's Health Ministry is looking to its new essential drugs policy to spur drug maker competition, along with the potential for mergers and acquisitions. The head of the ministry's program called the policy the central part of the nation's medical reform plan. He said establishing a competitive bidding process for drug makers to sell to the government means all makers of the same drug are not going to succeed. That means more mergers and acquisitions are likely to result in China, he said. Domestic generics makers are expected to be the major beneficiaries of the new policy. (Click here for more
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
EU Must Crack Down Harder On Fake Medical Devices, Says Innovator
Counterfeit copies of LifeVac Europe’s anti-choking devices have been registered on the EU’s EUDAMED database and continue to be sold on third-party platforms. Medtech Insight asked director of sales and marketing Matthew Banagan how the company deals with fake devices and what the authorities must do.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.